Gene therapy developer Freeline Therapeutics (NASDAQ: [[ticker:FRLN]]) has promoted Romuald Corbau to chief scientific officer. He joined London-based Freeline in 2017 as vice president of research. Amit Nathwani, the company’s founder and outgoing chief scientific officer, will remain with the company as clinical and scientific adviser and member of the board of directors. Freeline is currently in Phase 1/2 testing with FLT180a, an experimental hemophilia B gene therapy.
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
